WHAT WE DO?

Tuberculosis (TB) is a leading cause of death from infectious disease worldwide. In 2018 there were 10 million TB cases and 1.5 million people died from TB. Mozambique is on the list of countries with the highest TB incidence and mortality rate in the world. According to the World Health Organization (WHO) and the National Tuberculosis Control Program (PNCT), TB is currently the leading cause of death in HIV patients, and the high rate of drug-resistant TB (MDR-TB) is increasing progressively.

This context contributes to the prioritization of the Tuberculosis Area as one of the main research areas for CISM.

Main objectives

  • Generate laboratory and clinical capacity for the clinical development of drugs and vaccines against tuberculosis. Participate in the clinical development of new tools to combat and prevent tuberculosis (evaluation of new drugs, vaccines and diagnostic tests).

  • To better understand the epidemiology of tuberculosis in different population groups and to molecularly characterize the strains that circulate in the district of Manhiça.

  • Establish a tuberculosis surveillance platform in the district of Manhiça, in partnership with the National Tuberculosis Control Program.

 

PROJECTS

 

  • MULTIDRUG. Multidrug resistant tuberculosis: what is the role of HIV?

  • Preg-multidrug. Understanding the determinants of the effectiveness of HIV control strategies targeting HIV-infected pregnant women in Mozambique

  • TB REACH/Xpatial-TB - Improved case detection through TB ​​contact risk stratification by Xpert MTB/RIF® - results and spatial parameters in Mozambique (Xpatial-TB)

Other ongoing projects

DSCF0280.jpg

PUBLICATIONS

Area still under construction

IN

SHORTLY